AstraZeneca appoints Dr Euan Ashley as a Non-Executive Director

New appointment

AstraZeneca PLC (LON:AZN) has announced that with effect from 1 October 2020, Dr Euan Ashley is appointed as a Non-Executive Director and a member of the Science Committee.

Euan Ashley is Associate Dean and Professor of Cardiovascular Medicine and Genetics at Stanford University in California.  Dr Ashley’s research focuses on genetic mechanisms of cardiovascular health and disease.  In addition to wet bench science, his laboratory leverages artificial intelligence and digital health tools, working with biotechnology and technology partners in Silicon Valley, to advance both translational and clinical research.

Dr Ashley studied physiology and medicine at Glasgow University, completing his junior doctor training at Oxford University Hospitals NHS Trust, before undertaking a DPhil in cardiovascular cellular biology and molecular genetics at the University of Oxford.  In 2002, he moved to Stanford University to train in cardiology and advanced heart failure.

Dr Ashley has received many awards including recognition from the Obama White House for contributions to personalized medicine and the American Heart Association’s Medal of Honor for precision medicine.

Leif Johansson, Chairman of AstraZeneca, said: “We look forward to welcoming Euan to AstraZeneca and believe his scientific achievements and interests, which are well-aligned with our own BioPharmaceuticals R&D, together with his entrepreneurial experience on the US west coast will enable him to make a significant contribution to the Board’s work.”

Share on:

Latest Company News

AstraZeneca Q3 revenue rises 7% to $16.2bn as core earnings increase 19%

AstraZeneca reported third-quarter revenue growth of 7% to $16.2 billion, with Core EPS rising 19% to $2.79. The pharmaceutical...

AstraZeneca invests $2bn in Summit to accelerate ivonescimab development

AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in...

AstraZeneca’s Trixeo Aerosphere approved in EU for asthma

The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose...

AstraZeneca’s Klygefa recommended for EU approval in generalised myasthenia gravis

The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised...

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of...

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week...

    Search